# DESCRIPTION

## FIELD OF THE INVENTION

- define novel antimicrobial compounds

## BACKGROUND OF THE INVENTION

- introduce bovine mastitis
- describe current antibiotic therapies
- discuss multiple drug resistance
- motivate alternative antibacterial drugs
- describe bacterial riboswitches
- discuss limitations of current riboswitches
- introduce guanine riboswitches
- describe prior art on guanine riboswitches
- discuss limitations of prior art
- motivate need for novel antimicrobial targets

## SUMMARY OF THE INVENTION

- introduce guaA gene and GMP synthetase
- describe role of guanine riboswitch in gene expression
- present antibiotic-like compounds with antimicrobial activity
- define general formula 1.0 for compounds
- specify R1 to R10 substituents for general formula 1.0
- provide examples of tautomeric forms of compounds
- define specific embodiment of general formula 1.0
- introduce general formula 2.0 for compounds
- specify R1 to R12 substituents for general formula 2.0
- provide examples of tautomeric forms of compounds
- define specific embodiment of general formula 2.0
- introduce general formula 3.0 for compounds
- specify R1 to R14 substituents for general formula 3.0
- provide examples of tautomeric forms of compounds
- define specific embodiment of general formula 3.0
- introduce general formula 2.0a for compounds
- specify R2, R7, R8, R9, and R10 substituents for general formula 2.0a
- define specific embodiment of general formula 2.0a
- define compound formula 1.0a
- specify R7 and R2 embodiments
- describe application of compound formula 1.0a
- define compound formula 1.0
- specify R3, R6, R1, R2, R4, R5, and R8
- describe composition comprising compound formula 1.0
- define compound formula 2.0
- specify R9, R3, R1, R2, R11, and R12
- describe composition comprising compound formula 2.0
- define compound formula 3.0
- specify R10, R3, R1, R2, R9, and R12
- describe composition comprising compound formula 3.0
- specify specific embodiments of compound formulas
- describe composition comprising specific compounds
- specify additional compounds
- describe composition comprising additional compounds
- define composition
- specify uses of composition
- describe method of preventing or treating microbial infection
- specify pathogen and guanine riboswitch
- describe pharmaceutical composition
- specify non ribosylable ligand of guanine riboswitch
- describe method of preventing or treating microbial infection
- specify subject and pathogen
- describe use of non ribosylable ligand
- specify manufacture of medicament
- describe use of composition
- specify disinfection, sterilization, and/or antisepsis
- describe method of disinfecting and/or sterilizing object
- specify non ribosylable ligand of guanine riboswitch
- describe use of non ribosylable ligand
- specify object
- describe method of selecting pathogen
- specify non ribosylable ligand of guanine riboswitch
- describe method of identifying compound
- specify guanine riboswitch
- describe method of identifying compound
- specify binding of compound to guanine riboswitch
- describe method of preventing development of multi-drug resistance
- specify non ribosylable ligand of guanine riboswitch
- describe use of non ribosylable ligand
- specify manufacture of medicament
- describe use of composition
- specify non ribosylable ligand of guanine riboswitch
- describe composition
- specify object
- describe non ribosylable ligand of guanine riboswitch
- specify composition
- describe composition
- specify antibiotic, antiseptic, disinfectant, diluent, excipient, or pharmaceutically acceptable carrier
- describe kit
- specify instructions
- describe method of preparing compound of formula 2.02

## DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

- introduce gene guaA and its essentiality
- describe guanine riboswitch control of guaA expression
- present bioinformatic analysis of guanine riboswitches
- highlight unexpected discovery of guaA high expression
- describe microarray and quantitative PCR gene expression analysis
- introduce guanine-like compounds and their binding properties
- present binding and competition assays
- describe microarray gene expression analysis of compound effects
- highlight specificity and mechanism of compound modulation
- describe anti-bacterial effects of compounds

### Definitions

- define "a" and "an" in claims and specification
- define "comprising" and related terms
- define "molecule", "compound", "agent", and "ligand"
- define "rationally selected" and "rationally designed"
- define "subject" or "patient"
- define "pharmaceutically acceptable"
- define "carrier"
- describe pharmaceutical compositions and formulations
- describe routes of administration
- describe therapeutic formulations

### Oral

- describe oral therapeutic administration
- list excipients for tablets, dragees, and hard gelatin capsules
- list excipients for solutions and syrups

### Nasal

- describe administration by inhalation

### Transmucosal or Transdermal

- describe transmucosal or transdermal administration

### Parenteral

- describe injectable use
- list components for parenteral application
- describe biocompatible, biodegradable polymers
- describe liposomal suspensions

### Salts, Esters, Hydrates and Solvates

- define pharmacologically acceptable salts
- list examples of salts
- describe formation of salts
- define pharmacologically acceptable esters
- list examples of esters
- describe formation of esters
- describe conversion of esters to salts
- describe conversion of salts to esters
- define pharmacologically acceptable hydrates
- describe formation of hydrates
- define prodrugs
- describe formation of prodrugs
- list examples of prodrugs
- describe solvates
- describe formation of solvates
- list examples of solvates
- describe preparation of solvates
- describe analytical techniques for solvates
- describe purification of enantiomers
- describe separation of isomeric mixtures
- describe pharmaceutical compositions
- list additives in pharmaceutical compositions
- describe dosages
- describe factors affecting dosages
- describe toxicity and therapeutic efficacy
- describe determination of LD50 and ED50
- describe therapeutic index
- describe kits

### Stereoisomers, Enantiomers, Racemates, Tautomers

- describe stereoisomers, enantiomers, racemates, and tautomers

### Dosages

- describe dosages

### Toxicity and Therapeutic Efficacy

- describe toxicity and therapeutic efficacy
- describe determination of LD50 and ED50
- describe therapeutic index
- describe dosage range

## EXAMPLE 1

### guaA Expression in S. aureus Isolates from Infected Cows and from Milk

- relate invention to discovery of guaA expression
- describe DNA microarray gene expression analysis
- summarize results of microarray analysis
- describe real-time PCR analysis
- compare guaA expression to gyrB
- describe in vivo and in vitro experiments
- detail RNA extraction and hybridization
- confirm results with quantitative PCR
- summarize guaA expression during infection

## EXAMPLE 2

### Polycistronic RNA Encoding xpt/pbuX/guaB/guaA

- relate invention to discovery of polycistronic mRNA
- describe RT-PCR analysis of intergenic regions

## EXAMPLE 3

### Ability of Compounds of the Invention to Bind Guanine Riboswitches

- describe structure of guanine ligand and compounds
- describe binding affinity experiment
- summarize results of binding affinity experiment

## EXAMPLE 4

### Growth Inhibition of Bacterial Species Possessing a Guanine Riboswitch that Controls the Expression of the guaA Gene by Compounds of the Present Invention

- introduce compounds of the present invention
- describe growth inhibition of bacteria with guanine riboswitch
- describe lack of growth inhibition of bacteria without guanine riboswitch
- show examples of genes and operons controlled by guanine riboswitches
- describe method for identifying new guanine riboswitches
- show antibiograms of compounds on various bacterial species

### EXAMPLE 5

- introduce ribosylation reaction
- describe prevention of ribosylation by compounds of the present invention
- show antibiograms of compounds on E. coli and S. aureus
- describe effect of 6-thioguanine on bacterial growth
- summarize results of antibiogram experiments

### EXAMPLE 6

- introduce minimal inhibitory concentrations and bactericidal activities
- describe effect of compounds on S. aureus growth
- show growth curves of S. aureus with various compounds
- describe bactericidal activity of compounds on S. aureus
- summarize results of MIC and bactericidal activity experiments

### EXAMPLE 7

- describe bactericidal activity of compound 1.01 on S. aureus strains
- summarize results of bactericidal activity experiments

### EXAMPLE 8

- introduce mode of action of compounds of the present invention
- describe transcriptomic microarray analysis
- show effect of compound 1.01 on gene expression
- describe mechanism of action of compound 1.01
- summarize results of transcriptomic analysis

### EXAMPLE 9

- introduce in vivo infection model
- describe efficacy of compound 1.01 in treating S. aureus infection
- show results of in vivo infection experiments
- summarize results of in vivo infection experiments

### EXAMPLE 10

- introduce development of bacterial resistance
- describe inability of S. aureus to develop resistance to compound 1.01
- show results of resistance development experiments
- summarize results of resistance development experiments

### EXAMPLE 11

- introduce illustrative compounds of the present invention
- describe structural requirements for binding to guanine riboswitch

### EXAMPLE 12

- describe potential applications of compounds of the present invention

### EXAMPLE 13

- describe synthesis of compounds of the present invention

### EXAMPLE 14

- introduce bio-informatics search of guanine riboswitches
- describe consensus sequence used for search
- describe software used for search

### EXAMPLE 15

- demonstrate antibiotic activity of compounds
- describe MICs of compounds against S. aureus and E. coli

### EXAMPLE 16

- synthesize 5-Formamino-2-amino-4,6-dihydroxypyrimidine
- synthesize 5-Amino-6H-oxazolo[5,4-d]pyrimidin-7-one
- characterize compounds using NMR and MS

